<p>住友信托控股根据最新提交给证券交易委员会的第 13F 表格，在第二季度减持了百时美施贵宝（NYSE:BMY - Free Report）的持股比例 10.1%。该公司在该时期卖出了 511,497 股，持有该生物制药公司股票的股份为 4,562,969 股。在最近一个季度结束时，住友信托控股持有的百时美施贵宝股份价值 1.895 亿美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 警报：</p>
<ul>
<li>MarketBeat 周评 - 7/29 - 8/2</li>
</ul>
<p>其他大型投资者最近也买入和卖出了该公司的股票。麦肯锡金融公司在第四季度增持了百时美施贵宝的股份 37.9%。麦肯锡金融公司现在拥有 611,714 股该生物制药公司的股票，价值 3138.7 万美元，比上一时期增持了 168,135 股。泰奇财富合作伙伴有限责任公司在第四季度以约 349,000 美元的价格购入了百时美施贵宝的新股份。楽天証券株式会社在第四季度以 44,000 美元的价格购入了百时美施贵宝的新股份。大和证券集团在第四季度增加了对百时美施贵宝的持仓 6.8%。大和证券集团现在拥有 190,525 股该生物制药公司的股票，价值 977.6 万美元，比上一时期增持了 12,160 股。最后，Twin Capital Management Inc.在第四季度增持了百时美施贵宝的股份 13.4%。Twin Capital Management Inc.现在拥有 83,162 股该生物制药公司的股票，价值 426.7 万美元，比上一时期增持了 9,831 股。目前有 76.41% 的股份由机构投资者和对冲基金持有。</p>
<h2>百时美施贵宝股票表现</h2>
<p>周五午盘交易时，NYSE:BMY 的股价上涨 0.25 美元，达到 49.36 美元。公司股票交易量为 14,161,770 股，相比其平均交易量 15,904,074 股有所下降。百时美施贵宝的一年最低价为 39.35 美元，最高价为 63.41 美元。该股的 50 日移动平均价为 43.74 美元，200 日移动平均价为 46.58 美元。公司的资产负债比为 2.86，速动比率为 0.99，流动比率为 1.16。公司市值为 1,000.6 亿美元，市盈率为-15.92，市盈增长比率为 12.51，贝塔系数为 0.44。</p>
<ul>
<li>令人印象深刻的 Q2 业绩发布后，制药巨头股价上涨</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - Get Free Report）于 7 月 26 日星期五发布了季度业绩报告。该生物制药公司报告的季度每股收益为 2.07 美元，超过了 1.64 美元的共识预期 0.43 美元。百时美施贵宝的净利润率为-14.06%，股东权益回报率为 12.51%。该公司在该季度实现了 122 亿美元的收入，超过了 115.4 亿美元的分析师预期。与去年同期相比，该公司的季度收入增长了 8.7%。作为一组，股票研究分析师预计，百时美施贵宝今年财年的每股收益为 0.77 美元。</p>
<h2>百时美施贵宝股息公告</h2>
<p>该公司最近还宣布了季度股息，于 8 月 1 日星期四支付。截至 7 月 5 日星期五持股的股东将获得 0.60 美元的股息。除息日为 7 月 5 日星期五。这代表年度股息为 2.40 美元，股息率为 4.86%。百时美施贵宝的股息支付比率为-77.42%。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>3 只高股息股票，现在获得收入，未来获得增长</li>
</ul>
<p>BMY 近期成为多份研究报告的主题。BMO 资本市场将百时美施贵宝的目标股价从 55.00 美元下调至 48.00 美元，并在 4 月 26 日的研究报告中将其股票评级设定为&#34;市场表现&#34;。StockNews.com 在 7 月 29 日星期一的研究报告中，将百时美施贵宝的评级从&#34;买入&#34;提升为&#34;强烈买入&#34;。德意志银行股份公司将百时美施贵宝的目标股价从 53.00 美元下调至 45.00 美元，并在 7 月 23 日的报告中为该公司设定了&#34;持有&#34;评级。TD Cowen 将百时美施贵宝的目标股价从 45.00 美元上调至 53.00 美元，并在 8 月 12 日的研究报告中为该公司设定了&#34;持有&#34;评级。最后，康泰菲茨杰拉德重申了对百时美施贵宝的&#34;中性&#34;评级，并在 7 月 22 日的报告中将该股票的目标股价设定为 45.00 美元。一位股票研究分析师给予该股票卖出评级，十三位给予持有评级，两位给予买入评级，一位给予强烈买入评级。根据 MarketBeat.com 的数据，百时美施贵宝目前的共识评级为&#34;持有&#34;，平均目标股价为 54.86 美元。</p>
<p><strong>获取我们关于 BMY 的最新研究报告</strong></p>
<h2>百时美施贵宝简介（免费报告）</h2>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、市场、分销和销售生物制药产品。其产品涵盖血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者中卒中/全身栓塞风险，并用于 DVT/PE 的治疗；Opdivo，用于多种抗癌适应症，包括膀胱、血液、CRC、头颈、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用于多发性骨髓瘤；Orencia，用于活动性类风湿关节炎和银屑病性关节炎；以及 Sprycel，用于费城染色体阳性慢性髓细胞白血病的治疗。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比百时美施贵宝更喜欢的股票</li>
<li>在 52 周高点盈利交易股票</li>
<li>这家小市值财富管理股票可能带来巨大回报</li>
<li>如何抓住股息增长的好处</li>
<li>Bumble 的估值创历史新低，它的命运能否改变？</li>
<li>5 个折扣机会供股息增长投资者选择</li>
<li>MarketBeat 周评 - 8/12 - 8/16</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ Elon 将改变美国经济？（来自 Porter &amp; Company）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3"/></p>
<h2>现在是否值得投资$1,000 美元购买百时美施贵宝？</h2>
<p>在考虑购买百时美施贵宝之前，您需要听到这个消息。</p>
<p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票，而百时美施贵宝不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

百时美施贵宝

<p>三井住友信托控股有限公司（Sumitomo Mitsui Trust Holdings Inc.）减持百时美施贵宝（Bristol-Myers Squibb，NYSE:BMY）的股份 10.1%，持有约 456 万股，价值 5 亿美元，出售了 511,497 股。百时美施贵宝的股价表现波动，分析师对其给出不同评级和价格目标。该公司第二季度每股收益为 1.07 美元，超出预期，并宣布每股 0.60 美元的季度股息，收益率为 4.86%。机构投资者持有该股的 76.41%，反映出对这家生物制药公司的重大兴趣</p>

<p>Sumitomo Mitsui Trust Holdings Inc. decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 4,562,969 shares of the biopharmaceutical company's stock after selling 511,497 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.23% of Bristol-Myers Squibb worth $189,500,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>住友信托控股根据最新提交给证券交易委员会的第 13F 表格，在第二季度减持了百时美施贵宝（NYSE:BMY - Free Report）的持股比例 10.1%。该公司在该时期卖出了 511,497 股，持有该生物制药公司股票的股份为 4,562,969 股。在最近一个季度结束时，住友信托控股持有的百时美施贵宝股份价值 1.895 亿美元。</p>
</div><p>Get <strong>Bristol-Myers Squibb</strong> alerts:</p>
<ul>
<li>MarketBeat Week in Review – 7/29 - 8/2</li>
</ul>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 警报：</p>
<ul>
<li>MarketBeat 周评 - 7/29 - 8/2</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Mackenzie Financial Corp raised its holdings in shares of Bristol-Myers Squibb by 37.9% during the fourth quarter. Mackenzie Financial Corp now owns 611,714 shares of the biopharmaceutical company's stock valued at $31,387,000 after purchasing an additional 168,135 shares during the period. Tyche Wealth Partners LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth about $349,000. Rakuten Securities Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth $44,000. Daiwa Securities Group Inc. grew its position in Bristol-Myers Squibb by 6.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 190,525 shares of the biopharmaceutical company's stock valued at $9,776,000 after buying an additional 12,160 shares during the period. Finally, Twin Capital Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 13.4% in the 4th quarter. Twin Capital Management Inc. now owns 83,162 shares of the biopharmaceutical company's stock worth $4,267,000 after purchasing an additional 9,831 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者最近也买入和卖出了该公司的股票。麦肯锡金融公司在第四季度增持了百时美施贵宝的股份 37.9%。麦肯锡金融公司现在拥有 611,714 股该生物制药公司的股票，价值 3138.7 万美元，比上一时期增持了 168,135 股。泰奇财富合作伙伴有限责任公司在第四季度以约 349,000 美元的价格购入了百时美施贵宝的新股份。楽天証券株式会社在第四季度以 44,000 美元的价格购入了百时美施贵宝的新股份。大和证券集团在第四季度增加了对百时美施贵宝的持仓 6.8%。大和证券集团现在拥有 190,525 股该生物制药公司的股票，价值 977.6 万美元，比上一时期增持了 12,160 股。最后，Twin Capital Management Inc.在第四季度增持了百时美施贵宝的股份 13.4%。Twin Capital Management Inc.现在拥有 83,162 股该生物制药公司的股票，价值 426.7 万美元，比上一时期增持了 9,831 股。目前有 76.41% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>Bristol-Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百时美施贵宝股票表现</h2>
</div><p>Shares of NYSE:BMY traded up $0.25 during midday trading on Friday, reaching $49.36. 14,161,770 shares of the company's stock traded hands, compared to its average volume of 15,904,074. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41. The stock has a 50 day moving average of $43.74 and a 200 day moving average of $46.58. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The company has a market cap of $100.06 billion, a price-to-earnings ratio of -15.92, a P/E/G ratio of 12.51 and a beta of 0.44.</p>
<ul>
<li>Pharma Giant's Shares Up After Impressive Q2 Earnings Release</li>
</ul>
<div class="lb-trans"><p>周五午盘交易时，NYSE:BMY 的股价上涨 0.25 美元，达到 49.36 美元。公司股票交易量为 14,161,770 股，相比其平均交易量 15,904,074 股有所下降。百时美施贵宝的一年最低价为 39.35 美元，最高价为 63.41 美元。该股的 50 日移动平均价为 43.74 美元，200 日移动平均价为 46.58 美元。公司的资产负债比为 2.86，速动比率为 0.99，流动比率为 1.16。公司市值为 1,000.6 亿美元，市盈率为-15.92，市盈增长比率为 12.51，贝塔系数为 0.44。</p>
<ul>
<li>令人印象深刻的 Q2 业绩发布后，制药巨头股价上涨</li>
</ul>
</div><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The business's revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - Get Free Report）于 7 月 26 日星期五发布了季度业绩报告。该生物制药公司报告的季度每股收益为 2.07 美元，超过了 1.64 美元的共识预期 0.43 美元。百时美施贵宝的净利润率为-14.06%，股东权益回报率为 12.51%。该公司在该季度实现了 122 亿美元的收入，超过了 115.4 亿美元的分析师预期。与去年同期相比，该公司的季度收入增长了 8.7%。作为一组，股票研究分析师预计，百时美施贵宝今年财年的每股收益为 0.77 美元。</p>
</div><h2>Bristol-Myers Squibb Dividend Announcement</h2>
<div class="lb-trans"><h2>百时美施贵宝股息公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 4.86%. Bristol-Myers Squibb's payout ratio is -77.42%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，于 8 月 1 日星期四支付。截至 7 月 5 日星期五持股的股东将获得 0.60 美元的股息。除息日为 7 月 5 日星期五。这代表年度股息为 2.40 美元，股息率为 4.86%。百时美施贵宝的股息支付比率为-77.42%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<ul>
<li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
<ul>
<li>3 只高股息股票，现在获得收入，未来获得增长</li>
</ul>
</div><p>BMY has been the topic of a number of recent research reports. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, April 26th. StockNews.com upgraded Bristol-Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a &#34;hold&#34; rating for the company in a report on Tuesday, July 23rd. TD Cowen lifted their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated a &#34;neutral&#34; rating and set a $45.00 target price on shares of Bristol-Myers Squibb in a report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of &#34;Hold&#34; and an average target price of $54.86.</p>
<div class="lb-trans"><p>BMY 近期成为多份研究报告的主题。BMO 资本市场将百时美施贵宝的目标股价从 55.00 美元下调至 48.00 美元，并在 4 月 26 日的研究报告中将其股票评级设定为&#34;市场表现&#34;。StockNews.com 在 7 月 29 日星期一的研究报告中，将百时美施贵宝的评级从&#34;买入&#34;提升为&#34;强烈买入&#34;。德意志银行股份公司将百时美施贵宝的目标股价从 53.00 美元下调至 45.00 美元，并在 7 月 23 日的报告中为该公司设定了&#34;持有&#34;评级。TD Cowen 将百时美施贵宝的目标股价从 45.00 美元上调至 53.00 美元，并在 8 月 12 日的研究报告中为该公司设定了&#34;持有&#34;评级。最后，康泰菲茨杰拉德重申了对百时美施贵宝的&#34;中性&#34;评级，并在 7 月 22 日的报告中将该股票的目标股价设定为 45.00 美元。一位股票研究分析师给予该股票卖出评级，十三位给予持有评级，两位给予买入评级，一位给予强烈买入评级。根据 MarketBeat.com 的数据，百时美施贵宝目前的共识评级为&#34;持有&#34;，平均目标股价为 54.86 美元。</p>
</div><p><strong>Get Our Latest Research Report on BMY</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 BMY 的最新研究报告</strong></p>
</div><h2>Bristol-Myers Squibb Profile (Free Report)</h2>
<div class="lb-trans"><h2>百时美施贵宝简介（免费报告）</h2>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、市场、分销和销售生物制药产品。其产品涵盖血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病。该公司的产品包括 Eliquis，用于降低非瓣膜性心房颤动患者中卒中/全身栓塞风险，并用于 DVT/PE 的治疗；Opdivo，用于多种抗癌适应症，包括膀胱、血液、CRC、头颈、RCC、HCC、肺部、黑色素瘤、MPM、胃和食道癌；Pomalyst/Imnovid，用于多发性骨髓瘤；Orencia，用于活动性类风湿关节炎和银屑病性关节炎；以及 Sprycel，用于费城染色体阳性慢性髓细胞白血病的治疗。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Bristol-Myers Squibb</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>This Small Cap Wealth Management Stock Could Provide Big Returns</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Bumble's Valuation Hits an All-Time Low, Can Its Fortunes Change?</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>MarketBeat Week in Review – 8/12 - 8/16</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比百时美施贵宝更喜欢的股票</li>
<li>在 52 周高点盈利交易股票</li>
<li>这家小市值财富管理股票可能带来巨大回报</li>
<li>如何抓住股息增长的好处</li>
<li>Bumble 的估值创历史新低，它的命运能否改变？</li>
<li>5 个折扣机会供股息增长投资者选择</li>
<li>MarketBeat 周评 - 8/12 - 8/16</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Elon to Transform U.S. Economy? (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ Elon 将改变美国经济？（来自 Porter &amp; Company）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8867&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元购买百时美施贵宝？</h2>
</div><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买百时美施贵宝之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户现在购买的股票，而百时美施贵宝不在名单上。</p>
</div><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中有一个 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

三井住友信托控股公司持有百时美施贵宝（纽约证券交易所代码：BMY）1.895 亿美元的持股